Pub Date : 2024-12-20DOI: 10.1053/j.gastro.2024.12.010
JM Heijdra Suasnabar, M.L. Mearin, M.E. van den Akker-van Marle
No Abstract
没有抽象的
{"title":"Reply to Wu et al","authors":"JM Heijdra Suasnabar, M.L. Mearin, M.E. van den Akker-van Marle","doi":"10.1053/j.gastro.2024.12.010","DOIUrl":"https://doi.org/10.1053/j.gastro.2024.12.010","url":null,"abstract":"No Abstract","PeriodicalId":12590,"journal":{"name":"Gastroenterology","volume":"21 1","pages":""},"PeriodicalIF":29.4,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142867010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-20DOI: 10.1053/j.gastro.2024.11.027
Lichao Yang, Ganglei Liu, Lianwen Yuan
No Abstract
没有抽象的
{"title":"Reevaluating the Association Between Neonatal Inflammatory Markers and Early-Onset IBD Risk","authors":"Lichao Yang, Ganglei Liu, Lianwen Yuan","doi":"10.1053/j.gastro.2024.11.027","DOIUrl":"https://doi.org/10.1053/j.gastro.2024.11.027","url":null,"abstract":"No Abstract","PeriodicalId":12590,"journal":{"name":"Gastroenterology","volume":"152 1","pages":""},"PeriodicalIF":29.4,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142867306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-20DOI: 10.1053/j.gastro.2024.10.049
Xi Shao, Jun Chen, Cuirong Zhu, Jun Li, Chengzi Huang
No Abstract
没有抽象的
{"title":"Analysis of “Inflammatory Markers at Birth and Risk of Early-Onset Inflammatory Bowel Disease”","authors":"Xi Shao, Jun Chen, Cuirong Zhu, Jun Li, Chengzi Huang","doi":"10.1053/j.gastro.2024.10.049","DOIUrl":"https://doi.org/10.1053/j.gastro.2024.10.049","url":null,"abstract":"No Abstract","PeriodicalId":12590,"journal":{"name":"Gastroenterology","volume":"19 1","pages":""},"PeriodicalIF":29.4,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142867312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-19DOI: 10.1053/j.gastro.2024.12.007
Sik Yu So, Kara Gross Margolis
No Abstract
没有抽象的
{"title":"Sugar in the First 1000 Days of Life: Link to Increased Chronic Disease Risks","authors":"Sik Yu So, Kara Gross Margolis","doi":"10.1053/j.gastro.2024.12.007","DOIUrl":"https://doi.org/10.1053/j.gastro.2024.12.007","url":null,"abstract":"No Abstract","PeriodicalId":12590,"journal":{"name":"Gastroenterology","volume":"11 1","pages":""},"PeriodicalIF":29.4,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142857689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-19DOI: 10.1053/j.gastro.2024.11.023
Palle B. Jeppesen, Tim Vanuytsel, Sukanya Subramanian, Francisca Joly, Geert Wanten, Georg Lamprecht, Marek Kunecki, Farooq Rahman, Thor S.S. Nielsen, Mark Berner-Hansen, Ulrich-Frank Pape, David F. Mercer
BACKGROUND AND AIMS
Glepaglutide is a long-acting GLP-2 analog developed to improve intestinal absorption in short bowel syndrome (SBS) patients. We conducted a trial to establish efficacy and safety of glepaglutide in reducing parenteral support (PS) needs in SBS patients with intestinal failure (IF).
METHODS
In an international, placebo-controlled, randomized, parallel-group, double-blind, phase 3 trial, SBS-IF patients requiring PS ≥3 days/week were randomized 1:1:1 to 24 weeks of glepaglutide 10 mg twice-weekly (TW) or once-weekly (OW), or placebo. PS volume was equivalently reduced if average urine volume of a 48-hour balance period exceeded baseline values by >10%.
RESULTS
106 patients were randomized and dosed. Glepaglutide TW significantly reduced weekly PS volumes from baseline to week 24 versus placebo (mean change of −5.13 vs. −2.85 L/week; P = .0039; primary endpoint). Results were similar across major anatomical subgroups. Glepaglutide TW was also superior to placebo for key secondary endpoints of proportion of patients achieving clinical response defined as ≥20% PS volume reduction from baseline to weeks 20 and 24 (65.7% vs. 38.9%; P = .0243), and patients achieving a reduction in days on PS ≥1 day/week from baseline to week 24 (51.4% vs. 19.4%; P = .0043). Complete PS weaning (“enteral autonomy”) was achieved for 5 patients (14%) receiving glepaglutide TW versus 0 for placebo patients. No statistically significant differences were shown for glepaglutide OW versus placebo for primary or key secondary endpoints. Significant glepaglutide benefits on patient-reported outcome (Patient Global Impression of Change) were shown. Glepaglutide was assessed to be safe and well tolerated.
CONCLUSION
Glepaglutide treatment in SBS-IF patients resulted in clinically relevant reductions in PS requirements and was well tolerated.
背景和目的格列鲁肽是一种长效GLP-2类似物，用于改善短肠综合征（SBS）患者的肠道吸收。我们进行了一项试验，以确定格列鲁肽在减少SBS肠衰竭（IF）患者肠外支持（PS）需求方面的有效性和安全性。方法在一项国际、安慰剂对照、随机、平行组、双盲、3期试验中，需要PS≥3天/周的SBS-IF患者以1:1:1的比例随机分配给格列鲁肽10mg，每周两次（TW）或每周一次（OW），或安慰剂。如果48小时平衡期的平均尿量超过基线值10%，则PS量也会相应减少。结果106例患者被随机分组并给药。从基线到第24周，与安慰剂相比，格列鲁肽TW显著降低了每周PS体积(平均变化为- 5.13 L/周vs - 2.85 L/周；P = 0.0039；主要终点)。主要解剖亚群的结果相似。格列鲁肽TW在达到临床缓解的患者比例（定义为从基线到第20周和第24周PS体积减少≥20%）的关键次要终点上也优于安慰剂(65.7% vs. 38.9%；P = 0.0243)，从基线到第24周，患者服用PS≥1天/周的天数减少(51.4% vs. 19.4%；P = .0043)。接受格列鲁肽TW治疗的5例患者（14%）实现了完全的PS断奶（“肠内自主”），而安慰剂患者为0例。格帕鲁肽OW与安慰剂在主要终点或关键次要终点上没有统计学上的显著差异。显示了显著的格帕鲁肽对患者报告的结果（患者总体变化印象）的益处。格列帕鲁肽被评估为安全且耐受性良好。结论：来帕鲁肽治疗SBS-IF患者可降低临床相关的PS需求，且耐受性良好。
{"title":"Glepaglutide, a Long-acting Glucagon-like Peptide-2 Analog, Reduces Parenteral Support in Patients with Short Bowel Syndrome: a Phase 3, Randomized, Controlled Trial","authors":"Palle B. Jeppesen, Tim Vanuytsel, Sukanya Subramanian, Francisca Joly, Geert Wanten, Georg Lamprecht, Marek Kunecki, Farooq Rahman, Thor S.S. Nielsen, Mark Berner-Hansen, Ulrich-Frank Pape, David F. Mercer","doi":"10.1053/j.gastro.2024.11.023","DOIUrl":"https://doi.org/10.1053/j.gastro.2024.11.023","url":null,"abstract":"<h3>BACKGROUND AND AIMS</h3>Glepaglutide is a long-acting GLP-2 analog developed to improve intestinal absorption in short bowel syndrome (SBS) patients. We conducted a trial to establish efficacy and safety of glepaglutide in reducing parenteral support (PS) needs in SBS patients with intestinal failure (IF).<h3>METHODS</h3>In an international, placebo-controlled, randomized, parallel-group, double-blind, phase 3 trial, SBS-IF patients requiring PS ≥3 days/week were randomized 1:1:1 to 24 weeks of glepaglutide 10 mg twice-weekly (TW) or once-weekly (OW), or placebo. PS volume was equivalently reduced if average urine volume of a 48-hour balance period exceeded baseline values by >10%.<h3>RESULTS</h3>106 patients were randomized and dosed. Glepaglutide TW significantly reduced weekly PS volumes from baseline to week 24 versus placebo (mean change of −5.13 vs. −2.85 L/week; <em>P</em> = .0039; primary endpoint). Results were similar across major anatomical subgroups. Glepaglutide TW was also superior to placebo for key secondary endpoints of proportion of patients achieving clinical response defined as ≥20% PS volume reduction from baseline to weeks 20 and 24 (65.7% vs. 38.9%; <em>P</em> = .0243), and patients achieving a reduction in days on PS ≥1 day/week from baseline to week 24 (51.4% vs. 19.4%; <em>P</em> = .0043). Complete PS weaning (“enteral autonomy”) was achieved for 5 patients (14%) receiving glepaglutide TW versus 0 for placebo patients. No statistically significant differences were shown for glepaglutide OW versus placebo for primary or key secondary endpoints. Significant glepaglutide benefits on patient-reported outcome (Patient Global Impression of Change) were shown. Glepaglutide was assessed to be safe and well tolerated.<h3>CONCLUSION</h3>Glepaglutide treatment in SBS-IF patients resulted in clinically relevant reductions in PS requirements and was well tolerated.","PeriodicalId":12590,"journal":{"name":"Gastroenterology","volume":"48 1","pages":""},"PeriodicalIF":29.4,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142857690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-19DOI: 10.1053/s0016-5085(24)05703-2
No Abstract
没有抽象的
{"title":"Elsewhere in The AGA Journals (Preview Section)","authors":"","doi":"10.1053/s0016-5085(24)05703-2","DOIUrl":"https://doi.org/10.1053/s0016-5085(24)05703-2","url":null,"abstract":"No Abstract","PeriodicalId":12590,"journal":{"name":"Gastroenterology","volume":"87 1","pages":""},"PeriodicalIF":29.4,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142849557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-19DOI: 10.1053/j.gastro.2024.11.026
Asbjørn M. Drewes, Jens B. Frøkjær, Søren S. Olesen, Vikesh K. Singh, Rupjyoti Talukdar, John A. Windsor
No Abstract
没有抽象的
{"title":"Pain in Chronic Pancreatitis: Navigating the Maze of Blocked Tubes and Tangled Wires","authors":"Asbjørn M. Drewes, Jens B. Frøkjær, Søren S. Olesen, Vikesh K. Singh, Rupjyoti Talukdar, John A. Windsor","doi":"10.1053/j.gastro.2024.11.026","DOIUrl":"https://doi.org/10.1053/j.gastro.2024.11.026","url":null,"abstract":"No Abstract","PeriodicalId":12590,"journal":{"name":"Gastroenterology","volume":"7 1","pages":""},"PeriodicalIF":29.4,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142849555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Population-based observational studies suggest that endoscopic screening may reduce upper gastrointestinal cancer mortality. We aimed to quantify the effect of endoscopy screening.
Methods
This is a community-based, multicenter, cluster randomized clinical trial conducted in both high-risk and non-high-risk areas of China. Randomization and recruitment occurred between 2015 and 2017, with follow-up conducted until 2022. The intervention was an invitation to receive endoscopic screening, as opposed to receiving usual-care (unscreened). In non-high-risk areas, only participants assessed as high-risk by risk scores in the screening group were invited for endoscopic screening. The primary outcome was the cumulative risk of death from upper gastrointestinal cancer, adjusted for baseline characteristics and cluster effects.
Results
A total of 234,635 participants were included in the intention-to-screen analysis, with median age of 52 years. In high-risk areas, 64,836 individuals from 81 clusters were randomized to screening group, 59,379 individuals from 82 clusters were randomized to control group. In non-high-risk areas, 58,367 individuals from 92 clusters were randomized to screening group, 52,053 individuals from 90 clusters were randomized to control group. Among high-risk areas, 480 (adjusted cumulative risk, 0.77%) died of upper gastrointestinal cancers within 7.5 years in screening group vs 545 (0.99%) deaths in control group (risk ratio, 0.78; 95% CI, 0.66-0.91). Among non-high-risk areas, adjusted risk was 0.26% (146 deaths) in screening group and 0.30% (149 deaths) in control group (risk ratio, 0.86; 95% CI, 0.65-1.13).
Conclusions
An invitation to endoscopic screening reduced upper gastrointestinal cancer mortality in high-risk areas. In non-high-risk areas, an invitation to endoscopic screening based on risk scores did not significantly decrease upper gastrointestinal cancer deaths, but longer follow-up time was required.
{"title":"Effect of an Endoscopy Screening on Upper Gastrointestinal Cancer Mortality: A Community-based Multicenter Cluster Randomized Clinical Trial","authors":"Changfa Xia, He Li, Yongjie Xu, Guizhou Guo, Xiaodong Yu, Wanying Wang, Shuguang Dai, Chunyun Dai, Yigong Zhu, Kun Jiang, Zhiyi Zhang, Junguo Hu, Guohui Song, Chao Chen, Haifan Xiao, Yanfang Chen, Ting Song, Shipeng Yan, Bingbing Song, Yutong He, Wanqing Chen","doi":"10.1053/j.gastro.2024.11.025","DOIUrl":"https://doi.org/10.1053/j.gastro.2024.11.025","url":null,"abstract":"<h3>Background and Aims</h3>Population-based observational studies suggest that endoscopic screening may reduce upper gastrointestinal cancer mortality. We aimed to quantify the effect of endoscopy screening.<h3>Methods</h3>This is a community-based, multicenter, cluster randomized clinical trial conducted in both high-risk and non-high-risk areas of China. Randomization and recruitment occurred between 2015 and 2017, with follow-up conducted until 2022. The intervention was an invitation to receive endoscopic screening, as opposed to receiving usual-care (unscreened). In non-high-risk areas, only participants assessed as high-risk by risk scores in the screening group were invited for endoscopic screening. The primary outcome was the cumulative risk of death from upper gastrointestinal cancer, adjusted for baseline characteristics and cluster effects.<h3>Results</h3>A total of 234,635 participants were included in the intention-to-screen analysis, with median age of 52 years. In high-risk areas, 64,836 individuals from 81 clusters were randomized to screening group, 59,379 individuals from 82 clusters were randomized to control group. In non-high-risk areas, 58,367 individuals from 92 clusters were randomized to screening group, 52,053 individuals from 90 clusters were randomized to control group. Among high-risk areas, 480 (adjusted cumulative risk, 0.77%) died of upper gastrointestinal cancers within 7.5 years in screening group vs 545 (0.99%) deaths in control group (risk ratio, 0.78; 95% CI, 0.66-0.91). Among non-high-risk areas, adjusted risk was 0.26% (146 deaths) in screening group and 0.30% (149 deaths) in control group (risk ratio, 0.86; 95% CI, 0.65-1.13).<h3>Conclusions</h3>An invitation to endoscopic screening reduced upper gastrointestinal cancer mortality in high-risk areas. In non-high-risk areas, an invitation to endoscopic screening based on risk scores did not significantly decrease upper gastrointestinal cancer deaths, but longer follow-up time was required.","PeriodicalId":12590,"journal":{"name":"Gastroenterology","volume":"26 1","pages":""},"PeriodicalIF":29.4,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142849552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：